CJC-1295 vs Ipamorelin: Evidence Comparison

Verifiable Claims: Side-by-Side

Each row states a claim that is supported by a specific peer-reviewed citation where one exists, or by an established pharmacodynamic mechanism class where the mechanism is shared across the class. PMIDs link to the corresponding PubMed record — open any of them to verify the underlying study directly. Tier badges follow the four-tier evidence language used across all PeptideDecoded content (human RCT → human observational → animal/preclinical → mechanistic/anecdote).

Claim	CJC-1295 evidence	Ipamorelin evidence
Receptor target & mechanism class	Strong (mechanistic)Long-acting GHRH analog, offered with or without a Drug Affinity Complex (DAC) that binds serum albumin to extend plasma half-life. Acts at the pituitary GHRH receptor and amplifies endogenous GH pulsatility without replacing it. Receptor pharmacology is the Sermorelin-set GHRH-receptor mechanism class. PMID: 7527273	Strong (mechanistic)Selective ghrelin-receptor GHRP. Binds the somatotroph GHS-R1a ghrelin receptor with high selectivity, releasing GH without raising ghrelin or cortisol (and without the FSH/LH/TSH cross-reactivity seen in earlier GHRPs like GHRP-6). Receptor pharmacology well characterized. PMID: 9783708
GH pulsatility in healthy adults (pharmacodynamic baseline)	Mechanism-class onlyCJC-1295 acts at the same GHRH receptor as Sermorelin — mechanism-class extension of the Walker 1994 Sermorelin finding (PMID: 7527273). No Sermorelin-set citation supports CJC-1295-specific GH-pulse magnitude data in humans.	Established (human pharmacodynamic)Raun 1998 characterized Ipamorelin-induced selective GH release in healthy adults — the ghrelin-receptor mechanism class without FSH/LH/TSH cross-reactivity seen in earlier GHRPs. The pharmacodynamic anchor for selective ghrelin-receptor agonists. PMID: 9783708
Pediatric GH-deficiency diagnostic stimulation	Not establishedNo published diagnostic-stimulation history for CJC-1295 in any population. The compound is referenced in the Ipamorelin deep-dive as a GHRH-receptor "synergist" but does not appear in the diagnostic-stimulation literature.	Not establishedNo published diagnostic-stimulation history for Ipamorelin in the Sermorelin-set citations. Ipamorelin's Raun 1998 healthy-volunteer data is a GH-pulse pharmacodynamic anchor, not a GH-deficiency diagnostic-test trail.
Half-life / dosing-frequency rationale	Mechanism onlyDAC-modified CJC-1295 binds serum albumin to extend half-life (community-reported multi-day window); non-DAC CJC-1295 has a longer half-life than Sermorelin but shorter than the DAC variant. Pharmacokinetics only; no Sermorelin-set citation supports CJC-1295-specific human half-life figures. PMID: 7527273	Mechanism onlyShort plasma half-life — community-reported nightly subcutaneous dosing in two-pulse (AM/PM) protocols attempts to track the natural nocturnal GH pulse window. Pharmacokinetics only; the Raun 1998 paper establishes mechanism, not chronic-dose human PK in adults. PMID: 9783708
Endogenous GH-pulse preservation vs replacement	Pharmacologically plausibleSame GHRH receptor as Sermorelin — same upstream pulse-amplification class. The longer half-life means the GH pulse profile tracks less closely to the natural nocturnal GH-peak window; community concerns include potential dysregulation of the endogenous pulse architecture. No Sermorelin-set citation supports this claim for CJC-1295 specifically. PMID: 7527273	Established (mechanistic)Selective ghrelin-receptor GHRPs amplify the natural pituitary pulse architecture by acting at the GHS-R1a somatotroph receptor — preserves the endogenous GHRH output but stimulates GH release through a parallel receptor pathway. The pharmacodynamic anchor established in Raun 1998. PMID: 9783708
Sleep architecture / slow-wave recovery	Mechanism onlyGH pulsatility → slow-wave sleep is mechanistic, not RCT-established for either peptide. CJC-1295's longer half-life means the GH-pulse profile is decoupled from the nocturnal slow-wave window — a pharmacokinetic concern, not an established outcome for CJC-1295.	Mechanism onlyIpamorelin community interest focuses on sleep and recovery training, but no published RCT validates the sleep-architecture / slow-wave claim. Raun 1998 establishes mechanism; the body-comp / sleep / training-recovery outcomes remain mechanism-only extrapolation.
Body composition / fat loss / muscle gain	NoneGH elevation is a surrogate, not an outcome. Zero published human RCTs using body-composition endpoints for CJC-1295.	NoneGH elevation is a surrogate, not an outcome. Zero published human RCTs using body-composition endpoints for Ipamorelin — the Raun 1998 data establishes pharmacodynamics, not body-comp outcomes.
Anti-aging / longevity outcomes	NoneGH-axis pharmacology is a surrogate, not an outcome. Zero published human RCTs for any longevity endpoint. CJC-1295 has never been FDA approved for any indication.	NoneGH-axis pharmacology is a surrogate, not an outcome. Zero published human RCTs for any longevity endpoint — the GHRP community interest in anti-aging is mechanistic extrapolation only.
Human randomized controlled trial (any efficacy indication)	NoneZero published peer-reviewed human RCTs for adult GH-pulse support, body composition, anti-aging, sleep, or training-recovery efficacy as of August 2026. No Sermorelin-set citation supports CJC-1295-specific efficacy RCTs.	NoneZero published peer-reviewed human RCTs for adult GH-pulse support, body composition, anti-aging, sleep, or training-recovery efficacy as of August 2026. Raun 1998 is the only Ipamorelin pharmacodynamic citation in the underlying deep-dive — mechanism, not efficacy outcome.
WADA status	Prohibited (S2 — GH-Releasing Factors subcategory, at all times)	Prohibited (S2 — GH-Releasing Factors / GHRP subcategory, at all times)
FDA status	Not approved. Has never been FDA approved for any indication. No compounding monograph; subject to the July 2026 FDA reclassification review.	Not approved. Has never been FDA approved for any indication. No compounding monograph; subject to the July 2026 FDA reclassification review.

Citations reused from the CJC-1295 and Ipamorelin deep-dives — PMIDs are limited to PubMed identifiers 7527273 (Walker 1994, GHRH-receptor Sermorelin context), 8834260 (Reutens 1996, pediatric GH-deficiency diagnostic stimulation) and 9783708 (Raun 1998, selective ghrelin-receptor GH-pulse anchor). No new citations introduced. CJC-1295 statements are restricted to the GHRH-receptor mechanism class and regulatory context already documented across the Sermorelin and Ipamorelin deep-dives.

Dosing, Risk & Mechanism Matrix

Three side-by-side cards for direct comparison. The "Route / dosing" rows reflect community-reported ranges from peptide forums and compounding pharmacies — they are not clinically validated dosing protocols, and no human trial supports them.

CJC-1295

Long-acting GHRH analog · pituitary GHRH receptor binding, extended half-life via optional DAC

Mechanism Binds the pituitary GHRH receptor and amplifies the endogenous GH pulse architecture without suppressing it. CJC-1295 without DAC offers a moderately extended half-life; CJC-1295 with DAC binds serum albumin and produces a multi-day exposure window. Pharmacodynamic action is shared with Sermorelin and characterized in healthy adults via the Walker 1994 anchor. PMID: 7527273

Route / dosing (community-reported) Subcutaneous injection, ~2 mg once-weekly is the most commonly reported DAC-modification community protocol. Non-DAC variants are typically dosed more frequently. The weekly schedule is the primary buyer-facing distinction from Ipamorelin — unvalidated in humans.

Risk profile Long-term safety unknown. No peer-reviewed human safety database for sustained supra-physiologic GH-pulse support. The longer half-life decouples the GH-elevation profile from the natural nocturnal pulse window — pharmacodynamic concern, not an established adverse-event database.

WADA status Prohibited (S2 — GH-Releasing Factors subcategory, at all times).

FDA status Not approved. Has never been FDA approved for any indication. No compounding monograph; sits in regulatory gray zone subject to the July 2026 FDA reclassification review of peptide hormones.

Best-supported use case No validated indication. CJC-1295 is commonly marketed as a "weekly" alternative to nightly GHRP dosing — a pharmacokinetic convenience, not a clinical efficacy finding.

Ipamorelin

Selective ghrelin-receptor GHRP · pituitary GHS-R1a somatotroph receptor — GH-pulse selectivity without raising ghrelin or cortisol

Mechanism Binds the somatotroph GHS-R1a ghrelin receptor with high selectivity — the same receptor class as GHRP-6 but without raising ghrelin or cortisol and without FSH/LH/TSH cross-reactivity. Acts in parallel to GHRH-receptor agonists like CJC-1295; both converge on GH release at the pituitary. PMID: 9783708

Route / dosing (community-reported) Subcutaneous injection, 200–300 mcg in two pulses per day (AM/PM) is the most commonly reported protocol — chosen to track a daytime and a pre-bed GH-pulse window. Originally characterized as a single-bolus IV diagnostic-stimulation agent in Raun 1998 healthy-volunteer studies. Unvalidated in humans for adult body composition, anti-aging, sleep, or training-recovery.

Risk profile Long-term safety unknown. No published human safety database for sustained supra-physiologic GH-pulse support in adults. The Raun 1998 study establishes acute tolerability in validated research settings only; community chronic-dose exposure is uncaptured.

WADA status Prohibited (S2 — GH-Releasing Factors subcategory / GHRPs, at all times).

FDA status Not approved. Has never been FDA approved for any indication. No compounding monograph; sits in regulatory gray zone subject to the July 2026 FDA reclassification review of peptide hormones.

Best-supported use case No validated adult indication. Ipamorelin is commonly co-administered with CJC-1295 in community GHRP + GHRH stacks on the rationale of "complementary receptors" — mechanistic appeal only, not a clinical efficacy finding.

Stacking Them

CJC-1295 + Ipamorelin · different receptors (GHRH + GHS-R1a), different half-lives — the GH-axis "combo" rationale

Mechanism CJC-1295 binds the pituitary GHRH receptor and amplifies the natural pulse at one receptor step; Ipamorelin binds the somatotroph GHS-R1a ghrelin receptor and amplifies at a parallel receptor step. Both converge on pituitary GH release but through different receptor classes. This is the only receptor-complementary GH-axis combination — and the only one whose pharmacology is frequently described as "synergistic" in the source deep-dives.

Route / dosing (community-reported) Typical community stacks combine Ipamorelin (200–300 mcg twice daily) with CJC-1295 (DAC variant, ~2 mg weekly). The pulse-amplification rationale is the appeal: two receptors, two half-lives, one GH-axis target. GH-axis community protocols commonly run 12–24 weeks. None validated in humans.

Risk profile No human safety data on the combination outside narrow GHRP / GHRH diagnostic protocols. Two different receptors produce receptor-diverse amplification of the same GH axis — safety and efficacy on the pair is unestablished. Regulatory exposure from two S2-prohibited GHRFs / GHRP stacks without an evidence base.

WADA status Both individually prohibited — CJC-1295 under S2 (GH-Releasing Factors), Ipamorelin under S2 (GHRPs). The combination does not change the regulatory status of either component — a positive test for either remains a positive test.

FDA status Neither peptide is approved. CJC-1295 has never been FDA approved; Ipamorelin has never been FDA approved. Both subject to the July 2026 FDA reclassification review of peptide hormones.

Best-supported use case No supported use case in combination. Mechanistic only — the "different receptors, different half-lives, one GH-axis" rationale is plausible but unsupported by published human efficacy data; regulatory exposure stacks without an evidence base.

When to Choose Which

Three honest verdicts. Each mirrors the same evidence-gap framing used in the underlying deep-dives — choosing one peptide over another does not establish human efficacy for either, it only frames where the mechanistic rationale is strongest.

Choose CJC-1295 if…

The buyer's limiting factor is weekly dosing and they accept a compound with no diagnostic-stim history, no human efficacy RCTs, and no FDA approval

CJC-1295's distinguishing feature is pharmacokinetic, not pharmacodynamic: the DAC modification (or the non-DAC longer-half-life variant) extends the GHRH-receptor occupancy profile beyond Sermorelin's short window — hence the weekly community-reported schedule. Acts at the same pituitary GHRH receptor as Sermorelin (Walker 1994, PMID: 7527273). Caveats: zero published peer-reviewed human RCTs for any indication; the longer half-life decouples the GH-elevation profile from the natural nocturnal pulse window (a pharmacodynamic concern); CJC-1295 has never been FDA approved for any indication; WADA S2-prohibited. Half-life is not a substitute for efficacy.

Choose Ipamorelin if…

The buyer's primary interest is a ghrelin-receptor GHRP with the only human pharmacodynamic anchor in the comparison (Raun 1998) and they accept the same zero-RCT and unapproved compounding profile

Ipamorelin's distinguishing feature is receptor-class + pharmacodynamic selectivity: it binds the GHS-R1a ghrelin receptor, releases GH without raising cortisol or ghrelin, and avoids the FSH/LH/TSH cross-reactivity seen in earlier GHRPs. Confirmed in healthy volunteers via Raun 1998 (PMID: 9783708). Caveats: zero published peer-reviewed human RCTs for any efficacy indication; community-reported protocols (200–300 mcg twice daily) are unvalidated; WADA S2-prohibited; never FDA approved. Mechanism is — clinical efficacy is not.

Consider the combination if…

The buyer is anchored to the "different receptors, different half-lives, one GH-axis" RATIONALE — and explicitly accepts zero human efficacy data for the stack

Combining CJC-1295 (GHRH-receptor long-acting GHRH analog) and Ipamorelin (ghrelin-receptor GHRP) is the canonical community "GHRH + GHRP" stack: CJC-1295 weekly for background GHRH-receptor occupancy (Walker 1994, PMID: 7527273), Ipamorelin twice daily for parallel ghrelin-receptor GH-pulse amplification (Raun 1998, PMID: 9783708). Caveats: this is the only receptor-complementary GH-axis pair in the catalog; the rationale is real mechanism complementarity at different receptors — but clinical safety and efficacy on the pair is unestablished; both peptides are WADA S2-prohibited (positive test on either remains a positive test); neither has ever been FDA approved; both subject to the July 2026 FDA reclassification review. Receptor-complementary mechanism is not a clinical-efficacy finding.

How to Read This Page

"Evidence tier" is the most important field in every claim above. Two peptides can share a use case while having radically different evidence behind that use case. The badge colors map to the same four-tier language used across all PeptideDecoded deep-dives:

Evidence tiers (high → none)

High (green) — large body of consistent, replicated animal studies; or human RCT data.
Med (yellow) — moderate body of animal data; some mechanism replication across independent labs.
Low (red) — limited animal data; or single-lab evidence without independent replication.
None (gray) — no published human RCT data; preclinical evidence only.

What the gaps mean

Receptor-complementary mechanism ≠ clinical efficacy. CJC-1295 + Ipamorelin act at different pituitary receptors — but "different receptors" is mechanistic rationale, not a clinical-benefit finding. GH elevation in either pathway is still a surrogate, not a validated outcome.
Zero human RCTs for body composition, anti-aging, sleep, or training-recovery for both. Either peptide = animal or mechanistic data only. Raun 1998 and Walker 1994 establish pharmacodynamics, not efficacy outcomes.
CJC-1295 has never been FDA approved; Ipamorelin has never been FDA approved. Neither peptide has a compounding monograph. Both subject to the July 2026 FDA reclassification review of peptide hormones.
WADA S2 is "at all times" for both. CJC-1295 is listed under GH-Releasing Factors; Ipamorelin under GHRPs. Legally the same category; positive test for either results in a ban with no TUE pathway.
Different receptors, different half-lives. Combining the two produces receptor-diverse amplification of the same GH axis — the only "synergistic" combination in the catalog. But receptor diversity is not efficacy: the safety and efficacy on the pair is unestablished; regulatory exposure stacks.

For deeper context on how to evaluate any peptide claim — peer review, COI checks, red flags, and a 5-question pre-purchase checklist — see How to Verify Peptide Claims and the Editorial Standards page.

When NOT to Use Either

Competitive athletes (WADA S2): CJC-1295 and Ipamorelin are both prohibited at all times under WADA S2 (GH-Releasing Factors / GHRPs subcategory — also covering GHRPs and Tesamorelin). A positive test for either results in a ban, and there is no Therapeutic Use Exemption (TUE) pathway for either compound. The WADA categorization is legally identical between CJC-1295 and Ipamorelin.

Anyone seeking an FDA-approved therapy: neither peptide is approved for any human indication. CJC-1295 has never been FDA approved; Ipamorelin has never been FDA approved. Both peptides have no compounding monograph and sit in regulatory gray zone subject to the July 2026 FDA reclassification review of peptide hormones. Stacking amplifies regulatory exposure without adding evidence.

Anyone needing proven human efficacy: zero published human RCTs for both peptides for adult body composition, anti-aging, sleep, or training-recovery efficacy as of August 2026. Community-reported outcomes are not clinical evidence. Receptor-complementary mechanism is not efficacy: combining CJC-1295 (GHRH-receptor) with Ipamorelin (GHS-R1a ghrelin-receptor) on the rationale of "different receptors, one GH-axis, one output" does not establish clinical benefit. If you need a therapy with validated human efficacy, neither peptide is the right starting point — much less the combination.

CJC-1295 vs Ipamorelin: Which GH-Axis Peptide Has the Stronger Evidence Stack?